Business
CORCEPT THERAPEUTICS PUBLISHES ABSTRACT IN THE JOURNAL OF THE ENDOCRINE SOCIETY
MENLO PARK, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery
About this update from Corcept Therapeutics Incorporated
[{"type":"text","content":"MENLO PARK, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced the publication of an abstract in the April-May supplemental issue of the Journal of the Endocrine Society (JES). The abstract describes the Phase 3 trial (entitled “GRADIENT”) of relacorilant in patients with Cushing’s syndrome caused by adrenal adenomas or hyperplasia. Corcept’s poster describing the trial had been accepted for presentation at the 2020 Annual Meeting of the Endocrine Society (ENDO), which has been cancelled.\n “We are excited to present the design of a Phase 3 trial of our selective cortisol modulator, relacorilant in patients whose Cushing’s syndrome is caused by an adrenal adenoma,” said Andreas Grauer, MD, Corcept’s Chief Medical Officer. “GRADIENT is the first randomized, double-blind, placebo-controlled trial in patients with this etiology of Cushing’s syndrome. These patients experience poor health outcomes despite having a more indolent course of disease.” GRADIENT (NCT04308590) has a planned enrollment of 130 patients at sites in the United States and Europe. Participants will receive either relacorilant or placebo for six months, with the primary endpoints being improvement in glucose metabolism and hypertension. Many of the investigators for relacorilant’s ongoing Phase 3 GRACE trial (NCT03697109) will also participate in GRADIENT. Our poster presentation of GRADIENT’s Phase 3 design is available at the Research & Pipeline / Publications tab of our website. Journal of the Endocrine Society Volume 4, Issue Supplement 1 April-May 2020GRADIENT: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of a Selective Glucocorticoid Receptor Modulator, Relacorilant, in Patients With Autonomous Cortisol Secretion Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia Richard J. Auchus, MD, PhD; Andreas Grauer, MD; Andreas G. Moraitis, MD University of Michigan, Ann Arbor, MI, USA; Corcept Therapeutics, Menlo Park, CA, USA About RelacorilantRelacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, one of the two receptors to which cortisol binds...